反应详情

This was prepared using the same procedure as for (4-(6-bromo-7-(4-(pyridin-3-ylmethyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)methanamine, but here using tert-butyl 4-(7-(4-benzylpiperidin-1-yl)-6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)benzylcarbamate (15 mg, 0.026 mmol), TFA (0.2 mL) and CH2Cl2 (1 mL). The same purification procedure gave the desired product (12 mg, 97%) as a colourless solid; δH (500 MHz, DMSO-d6) 1.40-1.48 (m, 2H, 2× piperidine CHAHB), 1.73 (d, br, J=11.7 Hz, 2H, 2× piperidine CHAHB), 1.79-1.85 (m, 1H, piperidine CH), 2.61 (app d, J=7.1 Hz, 2H, PhCH2), 3.31-3.36 (m, 2H, 2× piperidine NCHAHA), 3.79 (s, 2H, CH2NH2), 3.85 (app d, J=12.0 Hz, 2H, 2× piperidine NCHAHA), 7.20 (t, J=7.2 Hz, 1H, phenyl H-4), 7.23 (d, J=7.0 Hz, 2H, phenyl H-2 & H-6), 7.31 (t, J=7.5 Hz, 2H, phenyl H-3 & H-5), 7.48 (d, J=8.2 Hz, 2H, phenyl H-3′ & H-5′), 8.10 (d, J=8.2 Hz, 2H, phenyl H-2′ & H-6′), 8.21 (s, 1H, (s, 1H, imidazo[4,5-b]pyridine H-5).

1. customThis was prepared
2. customThe same purification procedure